Medpace Holdings, Inc. (MEDP)
- Previous Close
387.61 - Open
387.10 - Bid 399.12 x 100
- Ask 399.59 x 100
- Day's Range
381.35 - 400.94 - 52 Week Range
197.39 - 421.00 - Volume
256,208 - Avg. Volume
284,879 - Market Cap (intraday)
12.369B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
40.65 - EPS (TTM)
9.82 - Earnings Date Jul 22, 2024 - Jul 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
448.60
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
www.medpace.com5,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MEDP
Performance Overview: MEDP
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDP
Valuation Measures
Market Cap
12.37B
Enterprise Value
12.10B
Trailing P/E
40.69
Forward P/E
37.17
PEG Ratio (5yr expected)
2.20
Price/Sales (ttm)
6.47
Price/Book (mrq)
18.42
Enterprise Value/Revenue
6.16
Enterprise Value/EBITDA
31.67
Financial Highlights
Profitability and Income Statement
Profit Margin
15.92%
Return on Assets (ttm)
13.89%
Return on Equity (ttm)
61.35%
Revenue (ttm)
1.96B
Net Income Avi to Common (ttm)
312.32M
Diluted EPS (ttm)
9.82
Balance Sheet and Cash Flow
Total Cash (mrq)
407.01M
Total Debt/Equity (mrq)
23.55%
Levered Free Cash Flow (ttm)
405.63M
Research Analysis: MEDP
Company Insights: MEDP
MEDP does not have Company Insights